What is Zacks Research’s Estimate for HALO Q2 Earnings?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Zacks Research lifted their Q2 2025 earnings per share estimates for shares of Halozyme Therapeutics in a report issued on Tuesday, March 11th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings per share of $1.08 for the quarter, up from their previous forecast of $1.06. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q3 2025 earnings at $1.31 EPS, Q4 2025 earnings at $1.58 EPS, FY2025 earnings at $4.86 EPS, Q1 2026 earnings at $1.28 EPS, Q2 2026 earnings at $1.41 EPS, Q3 2026 earnings at $1.57 EPS, Q4 2026 earnings at $1.71 EPS and FY2026 earnings at $5.96 EPS.

Several other equities analysts have also issued reports on HALO. Wells Fargo & Company cut their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Benchmark restated a “buy” rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Finally, Piper Sandler lifted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $62.78.

Halozyme Therapeutics Stock Up 2.0 %

Shares of Halozyme Therapeutics stock opened at $62.27 on Friday. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The stock has a market cap of $7.67 billion, a price-to-earnings ratio of 18.15, a PEG ratio of 0.42 and a beta of 1.32. The firm’s 50-day moving average is $56.76 and its two-hundred day moving average is $54.76. Halozyme Therapeutics has a 1 year low of $37.73 and a 1 year high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 5,000 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the transaction, the director now owns 38,611 shares in the company, valued at $2,173,799.30. This trade represents a 11.46 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total value of $580,500.00. Following the sale, the senior vice president now directly owns 185,453 shares of the company’s stock, valued at approximately $10,765,546.65. This represents a 5.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 31,697 shares of company stock valued at $1,754,451 in the last three months. 2.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. CBIZ Investment Advisory Services LLC purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at $29,000. Heck Capital Advisors LLC acquired a new position in Halozyme Therapeutics during the fourth quarter valued at $29,000. Smartleaf Asset Management LLC boosted its holdings in Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 197 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in Halozyme Therapeutics during the 4th quarter worth about $69,000. Finally, Parkside Financial Bank & Trust raised its stake in shares of Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 322 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.